Distribution and elimination characteristics of 111In-DTPA-D-Phe1-octreotide and 111In-DTPA-L-Phe1-octreotide in rats

被引:10
|
作者
Laznickova, A [1 ]
Laznicek, M
Trejtnar, F
Melicharova, L
Suzuki, KH
Akizawa, H
Arano, Y
Yokoyama, A
机构
[1] Charles Univ, Fac Pharm, Res Ctr, Hradec Kralove 50005, Czech Republic
[2] Kyoto Univ, Fac Pharmaceut Sci, Sakyo Ku, Kyoto, Japan
关键词
In-111; DTPA-D-Phe(1)-octreotide; DTPA-L-Phe(1)-octreotide; biodistribution; bioelimination;
D O I
10.1007/BF03190403
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study compares distribution and elimination characteristics of In-111-DTPA-D-Phe(1)-octreotide and In-111-DTPA-L-Phe(1)-octreotide in rats and evaluated the effect of the replacement of the terminal L-phenylalanine by D-phenylalanine on pharmacokinetic profiles of the radiolabelled peptides. Both agents exhibited rapid radioactivity clearance from the blood and most organs and tissues with no systematic and significant differences in activity accumulation. The long-term retention and high radioactivity concentrations for both compounds under study were found in the kidneys and organs with a high density of somatostatin receptors, such as the pancreas and adrenals. The residence times in these organs were longer for In-111-DTPA-D-Phe(1)-octreotide in comparison with In-111-DTPA-L-Phe(1)-octreotide. The major elimination pathway for both radiolabelled peptides was relatively rapid excretion into the urine. Analysis of the renal handling by an employment of the perfused rat kidney showed that both peptides were eliminated mainly by the mechanism of glomerular filtration. Rat liver perfusion experiments confirmed a very low value of bile clearance of radioactivity for both agents under study.
引用
收藏
页码:37 / 43
页数:7
相关论文
共 50 条
  • [41] The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment
    Shi, W
    Buchanan, KD
    Johnston, CF
    Larkin, C
    Ong, YL
    Ferguson, R
    Laird, J
    CLINICAL ENDOCRINOLOGY, 1998, 48 (03) : 303 - 309
  • [42] Systemic radionuclide therapy using indium-111-DTPA-D-Phe(1)-octreotide in midgut carcinoid syndrome
    Fjalling, M
    Andersson, P
    ForsselAronsson, E
    Gretarsdottir, J
    Johanson, V
    Tisell, LE
    Wangberg, B
    Nilsson, O
    Berg, G
    Michanek, A
    Lindstedt, G
    Ahlman, H
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (09) : 1519 - 1521
  • [43] Radiation doses deriving from patients undergoing 111In-DTPA-D-Phe-1-octreotide scintigraphy -: Reply
    Smith-Jones, PM
    Havlik, E
    Kurtaran, A
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (04): : 443 - 444
  • [44] Ectopic Cushing's syndrome and pulmonary carcinoid tumour identified by [111In-DTPA-D-Phe1]octreotide
    Matte, J
    Roufosse, F
    Rocmans, P
    Schoutens, A
    Jacobovitz, D
    Mockel, J
    POSTGRADUATE MEDICAL JOURNAL, 1998, 74 (868) : 108 - 110
  • [45] D-lysine for reduction of renal [In-111-DTPA,D-Phe-1]-octreotide and [Y-90-DOTA,D-Phe-1,Tyr-3]octreotide uptake
    deJong, M
    Bernard, B
    Breeman, W
    Bakker, W
    Visser, T
    Macke, H
    Krenning, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 52 - 52
  • [46] Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe(1)-octreotide
    Andersson, P
    ForssellAronsson, E
    Johanson, V
    Wangberg, B
    Nilsson, O
    Fjalling, M
    Ahlman, H
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (12) : 2002 - 2006
  • [47] IN-111 ACTIVITY CONCENTRATION IN TISSUE SAMPLES AFTER INTRAVENOUS-INJECTION OF INDIUM-111-DTPA-D-PHE-1-OCTREOTIDE
    FORSSELLARONSSON, E
    FJALLING, M
    NILSSON, O
    TISELL, LE
    WANGBERG, B
    AHLMAN, H
    JOURNAL OF NUCLEAR MEDICINE, 1995, 36 (01) : 7 - 12
  • [48] Therapeutic efficacy and toxicity of In-111-DTPA-D-Phe-Octreotide in advanced neuroendocrine tumour patients
    Schipper, ML
    Gotthardt, M
    Béhé, M
    Arnold, R
    Behr, TM
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (02) : 292 - 292
  • [49] (111Indium-DTPA-D-Phe) octreotide scintigraphy in the diagnostic assessment of palpable breast lumps
    Parker, SJ
    Barker, CPG
    McLeod, MA
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S74 - S74
  • [50] DISTRIBUTION AND DOSIMETRY OF IN-111 DTPA-D-PHE-OCTREOTIDE IN MAN ASSESSED BY WHOLE-BODY SCINTIGRAPHY
    BAJC, M
    PALMER, J
    OHLSSON, T
    EDENBRANDT, L
    ACTA RADIOLOGICA, 1994, 35 (01) : 53 - 57